Ginkgo Bioworks (DNA 1.89%) has a lot going for it. It's a favorite of Cathie Wood's Ark Innovation ETF, it's a popular collaborator in the biopharma sector, and its positioning at the intersection of biotechnology, artificial intelligence (AI), and laboratory robotics means that it's exposed to a lot of exciting and value-enhancing developments.But does that make it a buy, or just another stock getting hyped by the tech-hungry investors of the current bull market? Here's what you need to know.Why this comp ...